Skip to content
DraconiticResearch
Search Sources API
190,335 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BYReviews in cardiovascular medicine

Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions

  • Pierre Sabouret1
  • Domenico Mario Giamundo2
  • Joanna Popiolek-Kalisz3
  • Luigi Spadafora4
  • Marco Bernardi4
  • Elad Asher5
  • Mamas A Mamas6
  • Dan Atar7
  • Giuseppe Andò8
8 affiliations
  1. 1ACTION Study Group, Inserm UMRS1166, Heart Institute, Pitié-Salpetriere Hospital, Sorbonne University, 75013 Paris, France
  2. 2Division of Cardiology, Policlinico Casilino, 00169 Rome, Italy
  3. 3Clinical Dietetics Unit, Department of Bioanalytics, Medical University of Lublin, 20-059 Lublin, Poland
  4. 4Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy
  5. 5Jesselson Heart Center, Shaare Zedek Medical Center, The Eisenberg R&D Authority, and Faculty of Medicine, Hebrew University of Jerusalem, 9103102 Jerusalem, Israel
  6. 6Keele Cardiac Research Group, Centre for Prognosis Research, Keele University, ST5 5BG Stoke-on-Trent, UK
  7. 7Department of Cardiology, Oslo University Hospital, 0450 Oslo, Norway
  8. 8Department of Clinical and Experimental Medicine, University of Messina and Azienda Ospedaliera Universitaria Policlinico “Gaetano Martino”, 98125 Messina, Italy
Read full textPDFCite

Related

  1. Lipoprotein(a) After Myocardial Infarction: Residual Risk, Measurement, and the Unresolved Therapeutic Question
    Alexandra Gogan, Samuel Ardelean, Daniel Rus +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Artificial Intelligence in Voice Disorders: Current Landscape, Emerging Applications and Future Directions
    Rachel B. Kutler, Anaïs Rameau
    World Journal of Otorhinolaryngology-Head and Neck SurgeryPeer-reviewedCC BYFull text1 citedPhysiologyDOAJ
  3. Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration
    Eric J. Niesor, Marc Ditmarsch, Serge Rezzi +10
    Scientific ReportsPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaCrossref
  4. Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions
    Teng Yang, Takaya Shimura, Qing Wei +1
    Holistic Integrative OncologyPeer-reviewedCC BYFull textMedical imaging & radiologyDOAJ
  5. Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
    Muhammad Abdul Rehman, Malik Olatunde Oduoye, Davidson John Ozoemena +3
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{sabouret2026lipoproteina,
  title = {{Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions}},
  author = {Pierre Sabouret and Domenico Mario Giamundo and Joanna Popiolek-Kalisz and Luigi Spadafora and Marco Bernardi and Elad Asher and Mamas A Mamas and Dan Atar and Giuseppe Andò},
  journal = {Reviews in cardiovascular medicine},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13653194},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
AU  - Pierre Sabouret
AU  - Domenico Mario Giamundo
AU  - Joanna Popiolek-Kalisz
AU  - Luigi Spadafora
AU  - Marco Bernardi
AU  - Elad Asher
AU  - Mamas A Mamas
AU  - Dan Atar
AU  - Giuseppe Andò
PY  - 2026
DA  - 2026/08/28
JO  - Reviews in cardiovascular medicine
UR  - https://europepmc.org/article/PMC/PMC13653194
SN  - 1530-6550
ER  -